Stockscreener 앱 받기
4.35
7.94%
0.32
시간 외 거래:
4.35
전일 마감가:
$4.03
열려 있는:
$3.99
하루 거래량:
2.61M
Relative Volume:
2.61
시가총액:
$234.63M
수익:
$2.81M
순이익/손실:
$-97.34M
주가수익비율:
-2.4167
EPS:
-1.8
순현금흐름:
$-91.47M
1주 성능:
+9.85%
1개월 성능:
+45.48%
6개월 성능:
-31.82%
1년 성능:
-22.60%
1일 변동 폭
$3.955
$4.39
1주일 범위
$3.94
$4.64
52주 변동 폭
$2.86
$13.70
Fulcrum Therapeutics Inc Stock (FULC) Company Profile
명칭
Fulcrum Therapeutics Inc
전화
617-651-8851
주소
26 LANDSDOWNE STREET, CAMBRIDGE, MA
FULC을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
FULC
Fulcrum Therapeutics Inc
|
4.35 | 234.63M | 2.81M | -97.34M | -91.47M | -1.58 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Fulcrum Therapeutics Inc Stock (FULC) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-09-13 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2024-09-12 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2024-09-12 | 다운그레이드 | Cantor Fitzgerald | Overweight → Neutral |
| 2024-09-12 | 다운그레이드 | Leerink Partners | Outperform → Market Perform |
| 2024-09-12 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2024-09-12 | 다운그레이드 | Stifel | Buy → Hold |
| 2024-09-09 | 업그레이드 | BofA Securities | Underperform → Neutral |
| 2024-05-20 | 개시 | Cantor Fitzgerald | Overweight |
| 2024-03-13 | 개시 | RBC Capital Mkts | Outperform |
| 2023-09-25 | 개시 | Goldman | Neutral |
| 2023-08-23 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2023-08-22 | 업그레이드 | Stifel | Hold → Buy |
| 2023-05-04 | 다운그레이드 | Goldman | Buy → Neutral |
| 2023-03-10 | 다운그레이드 | Credit Suisse | Outperform → Neutral |
| 2023-03-10 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2023-03-09 | 다운그레이드 | Stifel | Buy → Hold |
| 2023-02-28 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2023-02-24 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2022-11-15 | 개시 | Goldman | Buy |
| 2022-03-08 | 개시 | Oppenheimer | Outperform |
| 2022-03-03 | 업그레이드 | BofA Securities | Underperform → Neutral |
| 2021-08-11 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2021-04-26 | 재개 | Credit Suisse | Outperform |
| 2021-03-22 | 개시 | Credit Suisse | Outperform |
| 2021-03-02 | 개시 | Stifel | Buy |
| 2020-10-16 | 개시 | Piper Sandler | Overweight |
| 2020-08-12 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2020-08-12 | 재확인 | H.C. Wainwright | Buy |
| 2020-08-12 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2020-06-19 | 다운그레이드 | BofA/Merrill | Buy → Neutral |
| 2020-06-17 | 개시 | BTIG Research | Buy |
| 2019-10-03 | 개시 | H.C. Wainwright | Buy |
| 2019-08-12 | 개시 | BofA/Merrill | Buy |
모두보기
Fulcrum Therapeutics Inc 주식(FULC)의 최신 뉴스
Fulcrum Therapeutics (NASDAQ:FULC) shareholders have endured a 77% loss from investing in the stock three years ago - Yahoo Finance
Analysts Set Fulcrum Therapeutics, Inc. (NASDAQ:FULC) PT at $9.33 - Defense World
Charles Schwab Investment Management Inc. Acquires 393,202 Shares of Fulcrum Therapeutics, Inc. (NASDAQ:FULC) - MarketBeat
FULC INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Fulcrum Therapeutics, Inc. and Encourages Investors to Contact the Firm! - The Eastern Progress Online
Fulcrum Therapeutics' SWOT analysis: stock faces headwinds after trial setback - Investing.com
Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Receives Consensus Rating of "Hold" from Brokerages - MarketBeat
Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Stock Holdings Trimmed by Fmr LLC - MarketBeat
Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Shares Sold by Fmr LLC - Defense World
Fulcrum Therapeutics Insider Purchases Yet To Pay Off Regardless Of Recent Strength - Simply Wall St
Jacobs Levy Equity Management Inc. Takes $721,000 Position in Fulcrum Therapeutics, Inc. (NASDAQ:FULC) - MarketBeat
BlackRock, Inc. Reduces Stake in Fulcrum Therapeutics Inc. - GuruFocus.com
Fulcrum Therapeutics' SWOT analysis: stock faces challenges after trial setback - Investing.com Nigeria
RA Capital Management L.P. Sells 1,380,605 Shares of Fulcrum Therapeutics, Inc. (NASDAQ:FULC) - MarketBeat
Braidwell LP Acquires New Stake in Fulcrum Therapeutics, Inc. (NASDAQ:FULC) - MarketBeat
Connor Clark & Lunn Investment Management Ltd. Makes New $474,000 Investment in Fulcrum Therapeutics, Inc. (NASDAQ:FULC) - MarketBeat
Fulcrum Therapeutics (FULC) Upgraded to Buy: Here's Why - MSN
Suvretta Capital Management LLC Sells 1,358,255 Shares of Fulcrum Therapeutics, Inc. (NASDAQ:FULC) - MarketBeat
Fulcrum Therapeutics to Participate in Upcoming December Conferences - The Manila Times
Fulcrum Therapeutics to Present at Three Major Healthcare Conferences in December | FULC Stock News - StockTitan
CAMP4 Therapeutics Corporation (CAMP) reports earnings - Quartz
Brokerages Set Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Price Target at $9.33 - MarketBeat
Facioscapulohumeral Muscular Dystrophy Market to Show Remarkable Growth Trends from 2024 to 2034, DelveInsight Reports | Fulcrum Therapeutics, aTyr Pharma, Fulcrum Therapeutics, Hoffmann-La Roche - The Globe and Mail
Fulcrum Therapeutics stock hits 52-week low at $2.87 By Investing.com - Investing.com Canada
Fulcrum Therapeutics stock hits 52-week low at $2.87 - Investing.com
HC Wainwright Analysts Increase Earnings Estimates for FULC - MarketBeat
Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Q3 2024 Earnings Call Transcript - MSN
Fulcrum Therapeutics, Inc. Announces Board Changes - Marketscreener.com
Simplify Asset Management Inc. Sells 323,518 Shares of Fulcrum Therapeutics, Inc. (NASDAQ:FULC) - MarketBeat
Fulcrum Therapeutics Third Quarter 2024 Earnings: US$0.35 loss per share (vs US$0.39 loss in 3Q 2023) - Yahoo Finance
Fulcrum Therapeutics Inc. (FULC) Tops Q3 EPS by 5c - StreetInsider.com
Fulcrum Therapeutics (NASDAQ:FULC) Receives Neutral Rating from HC Wainwright - MarketBeat
Expert Ratings For Fulcrum Therapeutics - Benzinga
Fulcrum Therapeutics Inc (FULC) Q3 2024 Earnings Call Highlights - GuruFocus.com
Fulcrum Therapeutics Inc (FULC) Q3 2024 Earnings Call Highlights: Strategic Advancements Amidst ... - Yahoo Finance
Fulcrum Therapeutics appoints new independent director - Investing.com India
Fulcrum Therapeutics appoints new independent director By Investing.com - Investing.com South Africa
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Third Quarter 2024 - The Manila Times
Fulcrum Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Fulcrum Therapeutics to Participate in the Stifel Healthcare Conference - The Manila Times
Fulcrum Therapeutics (FULC) to Present at Stifel Healthcare Conference | Investor Update | FULC Stock News - StockTitan
Fulcrum Therapeutics (FULC) Scheduled to Post Earnings on Wednesday - MarketBeat
Fulcrum Therapeutics to Host Third Quarter 2024 Financial Results Conference Call and Webcast on Wednesday, November 13, 2024 at 8:00 a.m. ET - The Manila Times
Fulcrum Therapeutics Inc (FULC) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Fulcrum Therapeutics Inc 주식 (FULC) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Tourangeau Greg | Principal Accounting Officer |
May 07 '24 |
Sale |
7.76 |
236 |
1,831 |
11,571 |
| Tourangeau Greg | Vice President, Finance |
Mar 08 '24 |
Sale |
11.72 |
4,884 |
57,219 |
11,807 |
| Sapir Alex | See Remarks |
Mar 04 '24 |
Buy |
11.35 |
43,360 |
492,028 |
43,360 |
2.88%
2.65%
자본화:
|
볼륨(24시간):